Market Chameleon (Fri, 19-Dec 3:42 AM ET)
Phibro Animal Health Corporation Announces Leadership Transition
Business Wire (Thu, 18-Dec 4:10 PM ET)
Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance
Business Wire (Wed, 5-Nov 4:22 PM ET)
Phibro Animal Health Corporation Declares Quarterly Dividend
Business Wire (Tue, 4-Nov 4:10 PM ET)
Business Wire (Thu, 30-Oct 1:00 PM ET)
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
Business Wire (Wed, 29-Oct 4:00 PM ET)
Business Wire (Thu, 9-Oct 4:30 PM ET)
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Phibro Animal Health - Class A trades on the NASDAQ stock market under the symbol PAHC.
As of December 31, 2025, PAHC stock price declined to $37.36 with 266,870 million shares trading.
PAHC has a beta of 1.13, meaning it tends to be more sensitive to market movements. PAHC has a correlation of 0.18 to the broad based SPY ETF.
PAHC has a market cap of $1.51 billion. This is considered a Small Cap stock.
Last quarter Phibro Animal Health - Class A reported $364 million in Revenue and $.73 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.13.
In the last 3 years, PAHC traded as high as $46.42 and as low as $9.40.
The top ETF exchange traded funds that PAHC belongs to (by Net Assets): IJR, VTI, IWM, VXF, SPSM.
PAHC has outperformed the market in the last year with a return of +80.4%, while the SPY ETF gained +17.2%. However, in the most recent history, PAHC shares have underperformed the stock market with its stock returning -7.4% in the last 3 month period and -7.5% for the last 2 week period, while SPY has returned +2.7% and +0.7%, respectively.
PAHC support price is $36.44 and resistance is $38.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PAHC shares will trade within this expected range on the day.
